Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry SALT LAKE CITY, M... Read More
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today anno... Read More
Myriad Genetics Reports Fourth Quarter Financial Results Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes Highli... Read More